Novel Insights into the Oncogenic Role and Clinical Significance of ORC6L in Breast Cancer

ORC6L has been implicated in various malignancies, and our preliminary bioinformatic analysis revealed its significant overexpression in breast cancer specimens. This study aims to investigate the biological functions and clinicopathological significance of ORC6L in breast cancer, and to evaluate its potential as a prognostic biomarker and therapeutic target.

ORC6L protein expression in breast cancer tissues was assessed via immunohistochemistry, followed by statistical analysis to determine its diagnostic and prognostic significance. To investigate the biological functions of ORC6L, a series of in vitro experiments were conducted in breast cancer cell lines. Cell proliferation was measured using colony formation, CCK-8, and EdU assays. Apoptosis was evaluated by flow cytometry. Cell migration and invasion were assessed via wound-healing and transwell assays, respectively.

ORC6L expression was markedly elevated in breast cancer tissues compared with adjacent non-tumor tissues. This elevated expression demonstrated high diagnostic value and was positively correlated with higher pathological grade. Moreover, ORC6L emerged as an independent predictor of poor survival outcomes in breast cancer patients. In vitro functional assays further revealed that ORC6L overexpression promoted proliferation, suppressed apoptosis, and enhanced migration, whereas ORC6L knockdown effectively inhibited proliferation, induced apoptosis, and attenuated migration.

ORC6L serves as a key driver of breast cancer progression, supporting its potential as a therapeutic target, though its independent prognostic value requires further validation.